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Background: Novobiocin is a coumarin antibiotic, which affects also eukaryotic cells inhibiting activity of Heat
shock protein 90 (Hsp90). The Hsp90 represents a molecular chaperone critical for stabilization and activation of
many proteins, particularly oncoproteins that drive cancer progression. Currently, Hsp90 inhibitors focus a significant
attention since they form a potentially new class of drugs in therapy of cancer. However, in the process of
tumorigenesis a significant role is played also by the microenvironment of the tumour, and, in particular, by
cancer-associated fibroblasts (CAFs). This study aimed at examination of the effect played by novobiocin on viability
of human gingival fibroblasts (HGF-1).
Methods: The studies were conducted using 24 h cultures of human gingival fibroblasts – HGF-1 (CRL-2014) in
Chamber Slides, in presence of 0.1, 0.5, 1.0, 2.5 or 5.0 mM novobiocin. Cell viability was evaluated using fluorescence
test, ATP assay and LDH release.
Results: Viability of HGF-1 was drastically reduced after 5 hour treatment with novobiocin in concentrations of
1 mM or higher. In turn, the percentage of LDH-releasing cells after 5 h did not differ from control value although it
significantly increased after 10 h incubation with 1 mM and continued to increase till the 20th hour.
Conclusions: The obtained data indicate that novobiocin may induce death of human gingival fibroblasts.
Therefore, application of the Hsp90 inhibitor in neoplastic therapy seems controversial: on one hand novobiocin
reduces tumour-associated CAFs but, on the other, it may induce a significant destruction of periodontium.
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Novobiocin represents a coumarin antibiotic produced
by Streptomyces spheroides and Streptomyces niveus strains
and manifesting activity against Gram-positive bacteria [1].
The antibiotic exerts mainly bacteriostatic activity, inhi-
biting function of ATP-dependent gyrase [2,3]. In ad-
dition, in recent years novobiocin was found to act also on
eukaryotic cells, blocking chaperone activity of 90 kDa
heat shock proteins (Hsp90) through competitive binding
to the Hsp90 C-terminal ATP binding site [4,5]. Due to in-
hibition of Hsp90, many oncoproteins linked to all six
hallmarks of cancer progression (angiogenesis, immortali-
zation, metastasis, impaired apoptosis, insensitivity to
antigrowth signals and autocrine growth) undergo deg-
radation in cancer cells [6]. Currently, inhibitors of Hsp90* Correspondence: tkarpin@interia.pl
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article, unless otherwise stated.are thought to represent promising agents, providing a
new class of drugs in cancer therapy. In parallel, recent
studies indicate that the microenvironment of the tumour
and activated fibroblasts in particular play a significant
role in the process of tumourigenesis [7-9]. These cancer-
associated fibroblasts (CAFs) may promote both tumour
growth and progression [9,10]. In parallel, it has already
been recognised that some oncological drugs may induce
periodontium destruction, resulting in a permanent archi-
tectural defect [11,12]. Gingival fibroblasts represent the
prevailing periodontal tissue cells while their injury during
cancer therapy may determine pathology in periodontium.
Nevertheless, data on effects of novobiocin on human fi-
broblasts still remain unavailable.
Taking the above into consideration, present investiga-
tions aimed at analysis of novobiocin effect on viability
of human gingival fibroblasts (HGF-1).Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Cell cultures
Gingival fibroblasts HGF-1 (CRL-2014, ATCC) were cul-
tured in T-25 culture vessels (Nunc), in an incubators at
the temperature of 37°C, in atmosphere of 5% CO2. Cul-
ture medium consisted of DMEM (ATCC) enriched with
10% FBS (Sigma-Aldrich).Fluorescence viability assay
Viability assays in gingival fibroblasts, HGF-1 employed
the fluorescence test of Live⁄Dead Viability⁄Cytotoxicity
Kit (Invitrogen, USA). The test allows to distinguish vi-
able cells (stained with green-fluorescent calcein-AM)
from dead cells (stained with red-fluorescent ethidium
homodimer-1). In the studies novobiocin (Sigma-Aldrich)
was used. The culture medium consisted of DMEM
(ATCC) enriched with 10% FBS (Sigma-Aldrich). The stu-
dies took advantage of 24 h cultures of gingival fibroblasts,
HGF-1, which following incubation were subjected to
triple rinsing. The tests in triple repetitions were con-
ducted in culture Lab-Tek Chamber Slides (Nunc) in pres-
ence of culture medium alone - control (0.5 × 106 cells of
HGF-1) and in presence of novobiocin (in concentrations
of 0.1, 0.5, 1, 2.5 or 5 mM/L/0.5 × 106 HGF-1 cells). The
samples were incubated for 20 h at 37°C in presence of
5% CO2. In addition, the samples were incubated with
1 mM/L novobiocin for 5 and 10 h. Following the incuba-
tion the cells were rinsed with culture medium and their
cell viability was assayed. The readout took advantage of
the fluorescence microscope, Nikon Eclipse E200 (magnif.
of 1000×).ATP assay
ATP content of HGF-1 gingival fibroblasts was evaluated
using a luminescence test (CellTiter-Glo Luminescent
Cell Viability Assay, Promega). The culture medium con-
sisted of DMEM (ATCC), enriched with 10% FBS (Sigma-
Aldrich). In the studies 24 h cultures of HGF-1 gingival
fibroblasts were used, which following incubation were
subjected to triple rinsing. The studies, in three repeti-
tions, were conducted in culture medium alone – the con-
trol (105 HGF-1 cells) and in presence of novobiocin (0.1,
0.5, 1, 2.5 or 5 mM/L/105 HGF-1 cells). The prepared
cells were incubated for 20 h at the temperature of 37°C
in presence of 5% CO2. Subsequently, they were rinsed
with culture medium and subjected to the test evaluating
ATP content. The results were read out using a lumin-
ometer (GloMax, Promega). In presence of ATP a light is
emitted which is read out in relative light units (RLU). In-
tensity of the emitted light quants is directly related to
quantity of ATP present in the test. Viability of fibroblasts
was calculated as a percentage of light intensity (RLU)
emitted from experimental samples to intensity emittedfrom control samples, which was set as representing 100%
viability.
LDH release
The tests of LDH release were conducted using CytoTox
96 Non-Radioactive Cytotoxicity Assay kits (Promega,
Madison). In the studies 24 h cultures of HGF-1 gingival
fibroblasts were used which, following incubation were
rinsed three times. The studies were performed in me-
dium alone – the control (105 HGF-1 cells) and in pres-
ence of novobiocin (0.1, 0.5, 1, 2.5 or 5 mM/L/105 HGF-1
cells). The tubes were centrifuged at 500 rpm for 4 min at
the temperature of 20°C. The prepared cells were incu-
bated for 20 h at the temperature of 37°C in presence of
5% CO2. In addition the samples with novobiocin at the
concentration of 1 mM/L were incubated for 5 and
10 hours. The studies were conducted as specified by the
producer. The results were read out as absorbance at
492 nm. The percentage of cytotoxicity was calculated as
a quotient of absorbance reflecting LDH release in experi-
mental samples to absorbance value reflecting LDH re-
lease in samples with maximum lysis.
Statistical methods
Results obtained in the studies were subjected to analysis
using the STATISTICA 8 software for Windows oper-
ational system. Comparative analysis of ATP levels and
studies on LDH release employed the unifactorial analysis
of variance (one-way ANOVA) with the Tukey-Kramer’s
test. Comparative analysis of gingival fibroblast viability
took advantage of the non-parametric Mann-Whitney’s
test and the Kruskal-Wallis’es test. A difference was con-
sidered significant when p < 0.05.
Results
In the studies percentage of viable HGF-1 fibroblasts in
control samples using the fluorescence test ranged be-
tween 94 and 99% (97.6 ± 2.32%), while in ATP assay the
average value in the control samples was taken as 100%.
In neither of the tests a significant difference could be
detected between viability in control samples and viability
of fibroblasts incubated with novobiocin at concentrations
of 0.1 mM or 0.5 mM. However, gingival fibroblast via-
bility was markedly reduced (p < 0.0001) following appli-
cation of novobiocin at the concentration of 1 mM. No
significant differences in fibroblast viability were detected
in samples treated with 1 mM, 2.5 mM or 5 mM novobio-
cin (Figures 1 and 2).
In control samples the percentage of LDH-releasing
cells ranged between 1 and 3.5% (2.8 ± 1.76%). No sig-
nificant difference could be detected between LDH levels
in the control samples and LDH levels in samples incu-
bated with novobiocin at the concentrations of 0.1 mM
or 0.5 mM. Levels of LDH were markedly increased
Figure 1 Viability of gingival fibroblasts (fluorescence test) after 20 h incubation with examined novobiocin concentrations. The studies
were conducted in triple repetitions. The obtained results represent mean values ± SD (denoted in bars).
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action at the concentration of 1 mM. No significant alter-
ations were noted in LDH levels in samples incubated
with 1 mM, 2.5 mM or 5 mM novobiocin (Figure 3).
Viability of HGF-1 fibroblasts treated with novobiocin
at the concentration of 1 mM obtained in fluorescence
test and that obtained in LDH release tests differed be-
tween each other: in fluorescence test viability of HGF-1
underwent a significant reduction already after 5 h and
it did not change in consecutive time points of testing,
in turn in LDH release assays the viability decreased sig-
nificantly after 10 h culture and continued to increase
till the 20th hour (Figure 4).
Discussion
The Hsp90 plays essential roles in the folding, matu-
ration and activity of many proteins that are involved in
signal transduction and transcriptional regulation [5]. TheFigure 2 Viability of gingival fibroblasts (ATP assay) after 20 h incuba
conducted in triple repetitions. The obtained results represent mean valuesproteins which are known to interact with Hsp90 include
glucocorticoid receptors [13], Akt/Protein kinase B and
Raf-1 [14], the tumor suppressor protein TP53 [15] and
NOS family members [16]. The anti-cancer effects in-
duced by novobiocin and its analogues through Hsp90 in-
hibition have already been well described [4,5]. Therefore,
Hsp90 chemical inhibitors may find application in onco-
logical therapy [17,18]. Moreover, application of Hsp90 in-
hibitors is considered in treatment of certain infectious
diseases, because in eukaryotic cells Hsp90 is essential for
the replication of obligatory intracellular parasites [19,20].
In recent years, development of neoplastic process has
been found to be contributed by CAFs present in tumour
stroma [9,10]. In parallel, fibroblasts represent prevail-
ing connective tissue cells which provide integrity to
its structure.
In this study we have examined for the first time effect
of novobiocin on viability of human gingival fibroblaststion with examined novobiocin concentrations. The studies were
± SD (denoted in bars).
Figure 3 Release of LDH in 20 h culture of gingival fibroblasts with the examined novobiocin concentrations. The studies were conducted in
triple repetitions. The obtained results represent mean values ± SD (denoted in bars).
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[21,22]. Using a fluorescent test and ATP assay we have
shown that novobiocin in doses of 0.1 and 0.5 mM failed
to alter cell viability. Nevertheless, 0.5 mM novobiocin
has insignificantly decreased viability of fibroblasts using
ATP assay. The test represents the most sensitive assay
of cell viability [23], which may explain differences in
the obtained results. Using both tests we have demon-
strated a significant decrease in HGF-1 viability following
their 20 h incubation with 1 mM novobiocin. Percentage
of viable fibroblasts following their 20 h incubation with
1.0, 2.5 and 5.0 mM novobiocin has amounted to 20-38%
and it has not been dependent on the dose of novobiocin.
In an earlier study by Calamia et al. [24], a significant
reduction was noted in viability of human chondrocytes
also in presence of 1 mM novobiocin. Results of Shelton
et al. [25] contrast with those of ours. The authors de-
monstrated that novobiocin in concentration of 0.252 mMFigure 4 Viability of gingival fibroblasts (fluorescence test and LDH te
incubation. The studies were conducted in triple repetitions. The obtainedmarkedly inhibited proliferation of Jurkat T-lymphocytes,
significantly reducing their viability. In turn, novobiocin at
the dose of 0.4353 mM significantly reduced proliferation
of K562 human erythroleukaemic cells [26]. However, the
data pertain leukaemic cells, which as neoplastic cells may
be particularly sensitive to Hsp90 inhibitors. The sugges-
tion has been supported by reports showing that Hsp90 in
cancer cells has a higher affinity for Hsp90 inhibition
drugs than the Hsp90 in normal cells [27].
The demonstrated by us novobiocin-mediated de-
creased viability of fibroblasts seems to result from in-
duction of an apoptotic response. The suggestion, in turn,
corresponds with the data indicating that novobiocin and
its derivatives may induce cell death along the apoptosis
pathway [24,26,28]. In our study we have conducted also
fibroblast viability tests following 5, 10 and 20 h treat-
ment with 1 mM novobiocin, using for the purpose the
fluorescence test and LDH assay. It has been alreadyst) in culture with 1 mM novobiocin after 5 h, 10 h and 20 h
results represent mean values ± SD (denoted in bars).
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hydrogenase (LDH) is released from necrotic cells and,
therefore, the use of LDH assay establishes cell death by
necrosis [23]. After 5 h incubation of fibroblasts with
1 mM novobiocin, the percentage of viable cells in fluor-
escence test has been significantly reduced and has shown
no statistical alterations in consecutive time points of test-
ing. In turn, LDH release upon 1 mM novobiocin treat-
ment has been significantly higher after 10 h than in
corresponding control and increased further till 20 h. The
results remain in contrast to the detected decrease in
fibroblast viability already after 5 h exposure, using fluor-
escence test and ATP assay. This may indicate that LDH
assay represents a test less sensitive than the remaining
two tests applied in the study, in accordance to the earlier
observation of Weyermann et al. [23]. However, on the
other hand it also seems probable that novobiocin in con-
centration of at least 1 mM induces fibroblast apoptosis,
leading after 10 hour incubation to post-apoptotic lysis of
the fibroblasts. The phenomenon of post-apoptotic lysis
has already been well described and referred to the post-
apoptotic change as secondary necrosis [29,30].
Conclusion
Data presented in this study indicate that novobiocin
may induce death of human gingival fibroblasts. There-
fore, application of this Hsp90 inhibitor drug in neo-
plastic therapy seems controversial: novobiocin on one
hand reduces tumour-associated CAFs and, on the
other, its application may lead to a severe destruction
of periodontium.
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